Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells

• Edris Choupani,

  Roles Conceptualization, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing

  Affiliation Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

  ⨯
• Zahra Madjd,

  Roles Investigation, Validation, Visualization, Writing – review & editing

  Affiliations Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran, Oncopathology Research Center, Iran University of Medical Sciences, (IUMS), Tehran, Iran

  ⨯
• Neda Saraygord-Afshari,

  Roles Conceptualization, Investigation, Supervision, Validation, Writing – original draft, Writing – review & editing

  Affiliation Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

  ⨯
• Jafar Kiani,

  Roles Validation, Writing – review & editing

  Affiliation Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

  ⨯
• Arshad Hosseini

  Roles Conceptualization, Validation, Writing – original draft, Writing – review & editing

  * E-mail: hoseini.a@iums.ac.ir

  Affiliation Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

  https://orcid.org/0000-0002-2077-0817

  ⨯